Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases

Basit Öğe Kaydı
dc.contributor.authorKronbichler, Andreas
dc.contributor.authorAnders, Hans-Joachim
dc.contributor.authorFernandez-Juarez, Gema Maria
dc.contributor.authorFloege, Jurgen
dc.contributor.authorGoumenos, Dimitrios
dc.contributor.authorSegelmark, Marten
dc.contributor.authorTesar, Vladimir
dc.date.accessioned2024-02-23T14:21:01Z
dc.date.available2024-02-23T14:21:01Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractCoronavirus disease 2019 (COVID-19) vaccine platforms are becoming available and are the most promising strategy to curb the spread of severe acute respiratory syndrome coronavirus 2 infections. However, numerous uncertainties exist regarding the pros and cons of vaccination, especially in patients with (immune-mediated) kidney diseases on immunosuppressive drugs. Here, members of the Immunonephrology Working Group of the European Renal Association-European Dialysis and Transplant Association discuss 13 frequently asked questions regarding the safety and efficacy of the most promising vaccine candidates. Post-marketing surveillance should be performed to estimate the rate of vaccine response (humoral and cellular) of different vaccine platforms and disease activity following the administration of COVID-19 vaccines. Some of the candidates induce signalling pathways, which also promote autoimmune kidney diseases, e.g. type I interferons in systemic lupus erythematosus. Efficacy estimates would thus far favour the use of selected COVID-19 vaccines, such as BNT162b2, mRNA-1273 or Gam-COVID-Vac. Humoral immune response after vaccination should be monitored using appropriate assays. Even in the absence of neutralizing antibodies, patients might be protected by a sufficient cellular immune response capable of reducing the severity of COVID-19. A reduced vaccine response after the use of CD20-depleting agents is anticipated and it is particularly important to discuss strategies to improve vaccine response with these patients. Distancing and shielding measures remain important, as not all vaccines fully protect from coronavirus infection. In-depth information about the most pressing vaccine questions is essential to reduce vaccine hesitancy of patients.en_US
dc.description.sponsorshipDeutsche Forschungsgemeinschaft [AN372/24-1]en_US
dc.description.sponsorshipThe Immunonephrology Working Group receives financial and logistic support from the ERA-EDTA. H.-J.A. was supported by the Deutsche Forschungsgemeinschaft (AN372/24-1).en_US
dc.identifier.doi10.1093/ndt/gfab064
dc.identifier.endpage1168en_US
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.issue7en_US
dc.identifier.pmid33693778en_US
dc.identifier.scopus2-s2.0-85129110641en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1160en_US
dc.identifier.urihttps://doi.org/10.1093/ndt/gfab064
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13416
dc.identifier.volume36en_US
dc.identifier.wosWOS:000733773900006en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCovid-19en_US
dc.subjectGlomerulonephritisen_US
dc.subjectImmunityen_US
dc.subjectImmune Responseen_US
dc.subjectVaccineen_US
dc.titleRecommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseasesen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu